Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6155MR)

This product GTTS-WQ6155MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6155MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13073MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ7704MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ14528MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ1821MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ5127MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ6421MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ6823MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ5197MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW